Security key
00972G207
Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX)
CUSIP: 00972G207
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Ordinary Shares, $0.000000005 par value
- Total 13F shares
- 7,250
- Total 13F value
- $877
- Share change
- -4,425,031
- SEC-reported price per share
- $0.12
- Number of holders
- 1
- Value change
- -$1,279,650
- Number of buys
- 1
- Number of sells
- 20
- Shares outstanding
- 94,284,567,045
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
1
Top holders
1
AKTX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Akari Therapeutics Plc SEC filings
Akari Therapeutics Plc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00972G207
Recent filing periods:
Ownership snapshot
Top reported holders of AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Hoyoung Huh
Disclosed value leader
Hoyoung Huh
Comparable rows
15/15
Latest evidence
02 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 18%
13D/G row: Hoyoung Huh
Showing 1-6 of 15 holder rows.
Quick read
Hoyoung Huh leads the comparable SEC ownership view at 18%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Hoyoung Huh's linked filing trail.
Comparable ownership
Top 5
Hoyoung Huh
18%
Samir R. Patel
10%
Raymond Prudo-Chlebosz
8.9%
ARMISTICE CAPITAL, LLC
0%
Cresset Asset Management, LLC
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Hoyoung Huh |
13D/G
3/4/5
Hoyoung Huh, M.D., Ph.D. · Director, 10%+ Owner
|
18%
|
$4,367,927,440
18,199,697,667 shares
|
+$2,377,245,520 | 02 Mar 2026 |
| Samir R. Patel |
13D/G
3/4/5
Director, 10%+ Owner
|
10%
|
$2,334,051,600
9,725,215,000 shares
|
$0 | 02 Mar 2026 |
| Raymond Prudo-Chlebosz |
13D/G
3/4/5
Ray Prudo, M.D. · Director
|
8.9%
|
$2,013,918,352
8,391,326,467 shares
|
+$831,534,160 | 02 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13F
Company
|
0%
|
$787,226
2,723,966 shares
|
— | 31 Dec 2025 |
| Cresset Asset Management, LLC |
13F
Company
|
0%
|
$237,693
822,468 shares
|
— | 31 Dec 2025 |
| Warberg Asset Management LLC |
13F
Company
|
0%
|
$88,709
308,340 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
7,250
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
21
Q1 2026 holders
1
Holder diff
-20
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend